| Buntanetap | ANVS-405; ANVS-401 | Phase 3 Clinical | Raptor Pharmaceutical | Alzheimer Disease; Chronic Traumatic Encephalopathy; Cognitive Dysfunction; Down Syndrome; Frontotemporal Dementia; Parkinson Disease | 詳細 |
| Florzolotau | F0-PBB3; PM-PBB3; [18F]APN-1607; [18F]MNI-958; APN-0000455; [18F]PM-PBB3; APN-1607; 18F-PM-PBB3; 18F-APN-1607 | Phase 3 Clinical | Aprinoia Therapeutics Ltd | Alzheimer Disease; Cognition Disorders; Cognitive Dysfunction; Diagnostic agents; Nerve Degeneration; Supranuclear Palsy, Progressive | 詳細 |
| Etalanetug | E-2814 | Phase 3 Clinical | Eisai Co Ltd | Alzheimer Disease; Dementia | 詳細 |
| Izaflortaucipir F-18 | PI-2620; 18F-PI-2620; [18F]PI-2620 | Phase 3 Clinical | Ac Immune Sa, Piramal | Alzheimer Disease; Brain Injuries, Traumatic; Cognitive Dysfunction; Frontotemporal Lobar Degeneration; Opioid-Related Disorders; Parkinson Disease; Supranuclear Palsy, Progressive | 詳細 |
| [F-18]Flornaptitril | [F-18]FDDNP; F-18-FNT-PET | Phase 3 Clinical | University Of California At Los Angeles | Alzheimer Disease; Chronic Traumatic Encephalopathy | 詳細 |
| XTR-006 | XTR-006 | Phase 3 Clinical | Beijing Xiantong International Technology Co Ltd | Alzheimer Disease; Tauopathies | 詳細 |
| Zagotenemab | LY-3303560 | Phase 2 Clinical | Eli Lilly And Company | | 詳細 |
| Posdinemab | JNJ-3657; JNJ-63733657 | Phase 2 Clinical | Johnson & Johnson Innovative Medicine | Alzheimer Disease; Cognitive Dysfunction; Dementia | 詳細 |
| [18F]GTP-1 | [18F]GTP-1 | Phase 2 Clinical | Genentech Inc | | 詳細 |
| [18F]THK-5105 | [18F]THK-5105 | Phase 2 Clinical | Tohoku University | | 詳細 |
| ISIS-814907 | BIIB-080; ISIS-814907; IONIS-MAPTRx; ISIS-BIIB4Rx; IONIS-BIIB4RX | Phase 2 Clinical | Biogen Inc, Ionis Pharmaceuticals Inc | Alzheimer Disease; Cognitive Dysfunction | 詳細 |
| Tilavonemab | C2N-8E12; ABBV-8E12 | Phase 2 Clinical | C2n Diagnostics Llc | Alzheimer Disease; Supranuclear Palsy, Progressive | 詳細 |
| Alzheimer's disease vaccine (Axon Neuroscience) | AADvac-1 | Phase 2 Clinical | Axon Biochemicals | Alzheimer Disease; Primary Progressive Nonfluent Aphasia; Supranuclear Palsy, Progressive | 詳細 |
| Semorinemab | MTAU-9937A; MTAU9937A; RG-6100; RO7105705; RO-7105705 | Phase 2 Clinical | Ac Immune Sa | | 詳細 |
| APN-1701 | [18F]AM-PBB3; 18F-AM-PBB3; APN-1701 | Phase 2 Clinical | Aprinoia Therapeutics Ltd, National Institute Of Radiological Sciences | Alzheimer Disease; Nerve Degeneration | 詳細 |
| VY-TAU-01 | VY-TAU01; VY-TAU-01; VY-7523 | Phase 2 Clinical | Voyager Therapeutics Inc | | 詳細 |
| Anti-tau antibody (Prothena) | BMS-986446; PRX-005 | Phase 2 Clinical | Prothena | Alzheimer Disease; Frontotemporal Dementia | 詳細 |
| MK-2214 | MK-2214 | Phase 2 Clinical | Merck Sharp & Dohme LLC | | 詳細 |
| BEY-2153 | BEY-2153 | Phase 2 Clinical | Beyondbio Inc | | 詳細 |
| Bepranemab | UCB-0107; RG6416 | Phase 2 Clinical | Ucb | Alzheimer Disease; Supranuclear Palsy, Progressive | 詳細 |
| [18F]THK-5117 | [18F]THK-5117 | Phase 2 Clinical | Tohoku University | | 詳細 |
| PNT-001 | PNT-001 | Phase 1 Clinical | Beth Israel Deaconess Medical Center | Alzheimer Disease; Brain Injuries, Traumatic | 詳細 |
| ReS19-T | ReS19-T | Phase 1 Clinical | Remynd | | 詳細 |
| Mecripyrine Hydrochloride | SCR-1693; Y-1A; Y-1 | Phase 1 Clinical | Jiangsu Simcere Pharmaceutical Co Ltd, NeuroDawn Pharmaceutical Co Ltd, Yantai Yene Pharma Co Ltd | Alzheimer Disease; Brain Neoplasms | 詳細 |
| Lu-AF87908 | Lu-AF87908; Lu-AF-87908 | Phase 1 Clinical | H. Lundbeck A/S | | 詳細 |
| RDC-5 | RDC-5 | Phase 1 Clinical | Chronos Therapeutics Ltd | Amyotrophic Lateral Sclerosis | 詳細 |
| MC-1 (Lilly) | MC-1 (Lilly) | Phase 1 Clinical | Eli Lilly And Company | | 詳細 |
| OLX-07010 | OLX07010 | Phase 1 Clinical | Oligomerix Inc | Alzheimer Disease; Dementia; Neurodegenerative Diseases; Supranuclear Palsy, Progressive | 詳細 |
| Protollin | | Phase 1 Clinical | The Brigham and Women's Hospital | | 詳細 |
| NB-02 | NB-02; DA-9803 | Phase 1 Clinical | Dong-A ST Co Ltd | Alzheimer Disease; Lymphoma, Non-Hodgkin | 詳細 |
| MAPT siRNA therapeutic (Eli Lilly and Company) | | Phase 1 Clinical | Eli Lilly And Company | Neurodegenerative Diseases | 詳細 |
| 18F-JSS20-183A | 18F-JSS20-183A | Phase 1 Clinical | University Of Pennsylvania | | 詳細 |
| ATC-102 | ATC-102; ATC102 | Phase 1 Clinical | Autotac Bio Inc | | 詳細 |
| AB-19 (AUTOTAC Bio) | AB-19 (AUTOTAC Bio) | Phase 1 Clinical | Autotac Bio Inc | Supranuclear Palsy, Progressive | 詳細 |
| AB-12 po (AUTOTAC Bio) | AB-12 po | Phase 1 Clinical | Autotac Bio Inc | | 詳細 |
| DNL-628 | OTV:MAPT; DNL-628 | Phase 1 Clinical | Denali Therapeutics Inc | | 詳細 |
| [89Zr]Zr-DFO-BIIB080 | [89Zr]Zr-DFO; [89Zr]Zr-DFO-ISIS-814907 | Phase 1 Clinical | Biogen Inc | | 詳細 |
| DA-7503 | DA-7503 | Phase 1 Clinical | Dong-A ST Co Ltd | | 詳細 |
| LY-3954068 | LY3954068; LY-3954068 | Phase 1 Clinical | Eli Lilly And Company | | 詳細 |
| AS-603 | S-603; AS-603; AS-S603 | Phase 1 Clinical | Amyloid Solution Inc | | 詳細 |
| ADEL-Y01 | ADEL-Y01 | Phase 1 Clinical | ADEL Inc, Oscotec Inc | Alzheimer Disease; Tauopathies | 詳細 |
| APNmAb-005 | APNmAb-005 | Phase 1 Clinical | Aprinoia Therapeutics Ltd | Alzheimer Disease; Nerve Degeneration; Tauopathies | 詳細 |
| AV-1959R/AV-1980R | 1959R + 1980R; AV 1959R + AV 1980R | Phase 1 Clinical | Nuravax | | 詳細 |
| NIO-752 | NIO-752 | Phase 1 Clinical | Novartis Pharma Ag | Alzheimer Disease; Cognitive Dysfunction; Neurodegenerative Diseases; Supranuclear Palsy, Progressive | 詳細 |
| 11C-PBB3 | 11C-PBB3 | Clinical | National Institute Of Radiological Sciences | | 詳細 |